Hypertensive APOL1 Risk Allele Carriers Demonstrate Greater Blood Pressure Reduction with Angiotensin Receptor Blockade Compared to Low Risk Carriers

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Sep 19

PMID 31532792

Citations 6

Authors

Patrick N Cunningham

Zhiying Wang

Megan L Grove

Rhonda M Cooper-DeHoff

Amber L Beitelshees

Yan Gong

John G Gums

Julie A Johnson

Stephen T Turner

Eric Boerwinkle

Arlene B Chapman

Affiliations

Soon will be listed here.

Abstract

Background: Hypertension (HTN) disproportionately affects African Americans (AAs), who respond better to thiazide diuretics than other antihypertensives. Variants of the APOL1 gene found in AAs are associated with a higher rate of kidney disease and play a complex role in cardiovascular disease.

Methods: AA subjects from four HTN trials (n = 961) (GERA1, GERA2, PEAR1, and PEAR2) were evaluated for blood pressure (BP) response based on APOL1 genotype after 4-9 weeks of monotherapy with thiazides, beta blockers, or candesartan. APOL1 G1 and G2 variants were determined by direct sequencing or imputation.

Results: Baseline systolic BP (SBP) and diastolic BP (DBP) levels did not differ based on APOL1 genotype. Subjects with 1-2 APOL1 risk alleles had a greater SBP response to candesartan (-12.2 +/- 1.2 vs -7.5 +/- 1.8 mmHg, p = 0.03; GERA2), and a greater decline in albuminuria with candesartan (-8.3 +/- 3.1 vs +3.7 +/- 4.3 mg/day, p = 0.02). APOL1 genotype did not associate with BP response to thiazides or beta blockers. GWAS was performed to determine associations with BP response to candesartan depending on APOL1 genotype. While no SNPs reached genome wide significance, SNP rs10113352, intronic in CSMD1, predicted greater office SBP response to candesartan (p = 3.7 x 10-7) in those with 1-2 risk alleles, while SNP rs286856, intronic in DPP6, predicted greater office SBP response (p = 3.2 x 10-7) in those with 0 risk alleles.

Conclusions: Hypertensive AAs without overt kidney disease who carry 1 or more APOL1 risk variants have a greater BP and albuminuria reduction in response to candesartan therapy. BP response to thiazides or beta blockers did not differ by APOL1 genotype. Future studies confirming this initial finding in an independent cohort are required.

Citing Articles

APOL1 Dynamics in Diabetic Kidney Disease and Hypertension.

Singhal P, Skorecki K Biomolecules. 2025; 15(2).

PMID: 40001508 PMC: 11853202. DOI: 10.3390/biom15020205.

Genome-Wide Approach of Gene-Nutrient Intake Interaction Study for Essential Hypertension in a Large Korean Cohort (KoGES).

Song Y, Choi J, Park J, Kwon Y, Hong K, Lee J Nutrients. 2024; 16(23).

PMID: 39683541 PMC: 11644644. DOI: 10.3390/nu16234147.

Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.

Sula Karreci E, Jacas S, Donovan O, Pintye D, Wiley N, Zsengeller Z Kidney Int. 2024; 106(6):1072-1085.

PMID: 39181397 PMC: 11585418. DOI: 10.1016/j.kint.2024.07.026.

APOL1 nephropathy - a population genetics success story.

Tabachnikov O, Skorecki K, Kruzel-Davila E Curr Opin Nephrol Hypertens. 2024; 33(4):447-455.

PMID: 38415700 PMC: 11139250. DOI: 10.1097/MNH.0000000000000977.

Multi-Institutional Implementation of Clinical Decision Support for and Genotyping in Antihypertensive Management.

Schneider T, Eadon M, Cooper-DeHoff R, Cavanaugh K, Nguyen K, Arwood M J Pers Med. 2021; 11(6).

PMID: 34071920 PMC: 8226809. DOI: 10.3390/jpm11060480.

References

Fisher N, Price D, Litchfield W, Williams G, Hollenberg N . Renal response to captopril reflects state of local renin system in healthy humans. Kidney Int. 1999; 56(2):635-41. DOI: 10.1046/j.1523-1755.1999.00579.x. View

Price D, Porter L, Gordon M, Fisher N, DeOliveira J, Laffel L . The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999; 10(11):2382-91. DOI: 10.1681/ASN.V10112382. View

Chapman A, Schwartz G, Boerwinkle E, Turner S . Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002; 61(3):1047-55. DOI: 10.1046/j.1523-1755.2002.00200.x. View

Wright Jr J, Bakris G, Greene T, Agodoa L, Appel L, Charleston J . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288(19):2421-31. DOI: 10.1001/jama.288.19.2421. View

Strop P, Bankovich A, Hansen K, Garcia K, Brunger A . Structure of a human A-type potassium channel interacting protein DPPX, a member of the dipeptidyl aminopeptidase family. J Mol Biol. 2004; 343(4):1055-65. DOI: 10.1016/j.jmb.2004.09.003. View

Zineh I, Beitelshees A, Gaedigk A, Walker J, Pauly D, Eberst K . Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004; 76(6):536-44. DOI: 10.1016/j.clpt.2004.08.020. View

Kraus D, Elliott G, Chute H, Horan T, Pfenninger K, Sanford S . CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol. 2006; 176(7):4419-30. DOI: 10.4049/jimmunol.176.7.4419. View

Honda M, Ogura Y, Toyoda W, Taguchi M, Nozawa T, Inoue H . Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. Biol Pharm Bull. 2006; 29(4):772-8. DOI: 10.1248/bpb.29.772. View

Canzanello V, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz G, Boerwinkle E, Turner S . Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2007; 21(1):61-6. DOI: 10.1038/ajh.2007.24. View

10.

Kopp J, Smith M, Nelson G, Johnson R, Freedman B, Bowden D . MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008; 40(10):1175-84. PMC: 2827354. DOI: 10.1038/ng.226. View

11.

Rau T, Wuttke H, MICHELS L, Werner U, Bergmann K, Kreft M . Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther. 2008; 85(3):269-72. DOI: 10.1038/clpt.2008.218. View

12.

Johnson J, Boerwinkle E, Zineh I, Chapman A, Bailey K, Cooper-DeHoff R . Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009; 157(3):442-9. PMC: 2671287. DOI: 10.1016/j.ahj.2008.11.018. View

13.

Li Y, Willer C, Sanna S, Abecasis G . Genotype imputation. Annu Rev Genomics Hum Genet. 2009; 10:387-406. PMC: 2925172. DOI: 10.1146/annurev.genom.9.081307.164242. View

14.

Jerng H, Dougherty K, Covarrubias M, Pfaffinger P . A novel N-terminal motif of dipeptidyl peptidase-like proteins produces rapid inactivation of KV4.2 channels by a pore-blocking mechanism. Channels (Austin). 2009; 3(6):448-61. PMC: 3607289. DOI: 10.4161/chan.3.6.10216. View

15.

Li X, Zhang J, Xie M, Liu M, Li B, Zhao Y . Association between DPP6 polymorphism and the risk of sporadic amyotrophic lateral sclerosis in Chinese patients. Chin Med J (Engl). 2010; 122(24):2989-92. View

16.

Koriyama H, Nakagami H, Katsuya T, Sugimoto K, Yamashita H, Takami Y . Identification of evidence suggestive of an association with peripheral arterial disease at the OSBPL10 locus by genome-wide investigation in the Japanese population. J Atheroscler Thromb. 2010; 17(10):1054-62. DOI: 10.5551/jat.4291. View

17.

Genovese G, Friedman D, Ross M, Lecordier L, Uzureau P, Freedman B . Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010; 329(5993):841-5. PMC: 2980843. DOI: 10.1126/science.1193032. View

18.

Freedman B, Kopp J, Langefeld C, Genovese G, Friedman D, Nelson G . The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol. 2010; 21(9):1422-6. PMC: 7391383. DOI: 10.1681/ASN.2010070730. View

19.

Turner S, Schwartz G, Chapman A, Beitelshees A, Gums J, Cooper-DeHoff R . Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010; 23(9):1014-22. PMC: 2941699. DOI: 10.1038/ajh.2010.98. View

20.

Li Y, Willer C, Ding J, Scheet P, Abecasis G . MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol. 2010; 34(8):816-34. PMC: 3175618. DOI: 10.1002/gepi.20533. View